Fig. 6From: Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in FranceProportion of patients with 28 day Angioedema Activity Score (AAS28) score of 0 at initiation, month 3, and month 6 (analyzed populaton)Back to article page